Evidence map›Paper›PMID 23248232›Full record

SynthesisPediatrics2013

Meta-analysis of LCPUFA supplementation of infant formula and visual acuity.

Ahmad Qawasmi, Angeli Landeros-Weisenberger, Michael H Bloch

Abstract readMeta-Analysis
In one paragraph

Synthesis in Pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Longchain polyunsaturated fatty acid supplementation in preterm infants.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmad QawasmiChild Study Center and cDepartment of Psychiatry, Yale University, New Haven, Connecticut 06520, USA. michael.bloch@yale.edu
Angeli Landeros-Weisenberger
Michael H Bloch

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Research Training for Medical Students & Physician-Scientists in Child PsychiatryR25MH077823 · NIMH · YALE UNIVERSITY · PI ANDRES S MARTIN · 2006 to 2026
$4.0M
Longitudinal Structural MRI Study of Adulthood Outcome in Tourette SyndromeK23MH091240 · NIMH · YALE UNIVERSITY · PI BLOCH, MICHAEL H · 2010 to 2014
$902k
NCRR NIH HHS UL1 RR024139NIMH NIH HHS 1K23MH091240-01NIMH NIH HHS K23 MH091240NIMH NIH HHS R25 MH077823
6 · The paper itself

Abstract

BACKGROUND AND

objectiveLong-chain polyunsaturated fatty acids (LCPUFAs) are hypothesized to affect visual acuity development in infants. Randomized controlled trials (RCTs) have been conducted to assess whether supplementation of LCPUFAs of infant formulas affects infant visual acuity. This meta-analysis was conducted to evaluate whether LCPUFA supplementation of infant formulas improves infants' visual acuity.

methodsPubMed and PsycInfo were searched for RCTs assessing the efficacy of LCPUFA supplementation of infant formulas on infant visual acuity. RCTs assessing the effects of LCPUFA supplementation on visual acuity (by using either visual evoked potential or behavioral methods) in the first year of life were included in this meta-analysis. Our primary outcome was the mean difference in visual resolution acuity (measured in logarithm of minimum angle of resolution [logMAR]) between supplemented and unsupplemented infants. We also conducted secondary subgroup analyses and meta-regression examining the effects of LCPUFA dose and timing, preterm versus term birth status, and trial methodologic quality.

resultsNineteen studies involving 1949 infants were included. We demonstrated a significant benefit of LCPUFA supplementation on infants' visual acuity at 2, 4, and 12 months of age when visual acuity was assessed by using visual evoked potential and at 2 months of age by using behavioral methods. There was significant heterogeneity between trials but no evidence of publication bias. Secondary analysis failed to show any moderating effects on the association between LCPUFA supplementation and visual acuity.

conclusionsCurrent evidence suggests that LCPUFA supplementation of infant formulas improves infants' visual acuity up to 12 months of age.

Indexed as

Dietary SupplementsAcyl Coenzyme AFatty Acids, UnsaturatedHumansInfant FormulaInfant, NewbornRandomized Controlled Trials as TopicVisual AcuityAcyl Coenzyme AFatty Acids, Unsaturated

Identifiers

PMID23248232
PMCPMC3529943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.